Confirmation of these positive results are planned in future Phase 3 trials.RODICA BUSUIANAND PATELCHRISTINE N. SANGCRAIG B. GRANOWITZPHILLIP L. BANKSPHILLIP PIERCEFRANKLIN W. SUNSUMA GOPINATHANDiabetes
同时,基于多个临床前模型中的有希望结果和有利的I期临床安全性,我们将探索LX9211在其他神经源性疼痛领域的机会。” 原文出处:Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain 原标题:糖尿病...